Trigyn Technologies Q1FY27 Revenue ₹252.76 Cr, PAT ₹3.49 Cr vs Loss ₹4.61 Cr
Trigyn Technologies reported consolidated revenue of ₹252.76 Crore for Q1FY27, up from ₹224.50 Crore year-on-year. Consolidated PAT turned positive at ₹3.49 Crore from a loss of ₹4.61 Crore. Standalone revenue was ₹37.99 Crore, and standalone loss narrowed to ₹2.48 Crore from ₹4.99 Crore.
The improved financial performance, particularly the turnaround in consolidated profit, is a positive development that could impact investor sentiment and the company's valuation.
The company has shown significant improvement in profitability, turning a consolidated loss into a profit and narrowing the standalone loss, alongside revenue growth.
Trigyn Technologies Limited announced its financial results for the quarter ended June 30, 2026. On a consolidated basis, the company reported a revenue of ₹25,275.74 Lakhs (₹252.76 Crore), an increase from ₹22,449.99 Lakhs (₹224.50 Crore) in the corresponding quarter of the previous year and ₹25,194.63 Lakhs (₹251.95 Crore) in the previous quarter.
The consolidated Profit After Tax (PAT) from continuing operations for the quarter stood at ₹348.75 Lakhs (₹3.49 Crore), a significant improvement from a Net Loss After Tax of ₹(460.87) Lakhs (₹-4.61 Crore) in the same quarter last year. This also marks an increase from the PAT of ₹63.21 Lakhs (₹0.63 Crore) in the previous quarter ended March 31, 2026.
On a standalone basis, the company's revenue for the quarter ended June 30, 2026, was ₹3,799.38 Lakhs (₹37.99 Crore), compared to ₹3,541.02 Lakhs (₹35.41 Crore) in the corresponding quarter of the previous year and ₹4,733.01 Lakhs (₹47.33 Crore) in the previous quarter. The standalone Loss After Tax for the quarter was ₹(247.98) Lakhs (₹-2.48 Crore), an improvement from the loss of ₹(499.02) Lakhs (₹-4.99 Crore) in the same quarter last year. This is also an improvement from the standalone Profit After Tax of ₹1,084.71 Lakhs (₹10.85 Crore) in the previous quarter ended March 31, 2026.
What to do with a filing like this
Trigyn Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Trigyn Technologies Limited. Read the original for the full detail.